CYTK

Cytokinetics Inc

Last Updated:

Q3 '20

Price

quotes and stock data delayed 15 minutes

Cash

$410.3M

Burn Rate (Qtr)

$3.2M

Company Profile

CYTK is developing potential medicines to improve the healthspan of people with devastating cardiovascular and neuromuscular diseases of impaired muscle function, like heart failure, hypertrophic cardiomyopathies (HCM), amyotrophic lateral sclerosis (ALS) and spinal muscular atrophy (SMA). By focusing on impacting the mechanics of muscle with investigational medicines that may improve strength, power, or performance, CYTK aspires to develop new treatment options that may dramatically improve the lives and functionality of people living with debilitating diseases.

Drug Pipeline

Click on drug name or indication to see upcoming trial info, prior data, and more general information

Drug | Disease (links)

Stage (next event)

Catalyst Date

OMECAMTIV MECARBIL

Heart Failure with Reduced Ejection Fraction (HFrEF)

Phase 3 Data

TBA

Reldesemtiv

Amyotrophic lateral sclerosis (ALS)

Phase 2 Initiation

TBD

CK-274

Hypertrophic Cardiomyopathies (HCM)

Phase 2 Data

End of 2020

Recent Posts

See what the community is saying - click to see full post

CYTK - Cytokinetics Regains Rights to Develop and Commercialize Omecamtiv Mecarbil and AMG 594 From Amgen

CYTK - How likely to meet exceptional efficacy?

*Disclaimer: Information provided on ampbiotechresearch.com and in any of our reports, products and services are for information only and are not investment advice. Please consult with an investment adviser and do your own diligence before making any investment decisions or taking any action.  By accessing this site, you agree to our Terms of Use and Privacy Policy that can be accessed here. Amp Core™ is a trademark of Amp Biotech Research, LLC

©2020 BY Amp Biotech Research

  • Twitter Social Icon
  • LinkedIn Social Icon